 Treatment of pediatric acute lymphoblastic leukemia ALL has advanced and the overall survival exceeds 80 nowadays. However the overall survival of high risk ALL remains 75-90, thus recent studies focus on treatment intensification according to the risk group. According to the previous reports, we designed a multicenter prospective trial for pediatric ALL. 